In previous animal studies, FGF21 was found to be essential for the weight control effect of glucagon agonists and attenuated hepatic steatosis, inflammation, and fibrosis in a NASH mouse model [32,33,34,35,36,37,38]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.